C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter C—Drugs: GeneralPart 211—Current Good Manufacturing Practice for Finished PharmaceuticalsSubpart J—Records and Reports

21 C.F.R. § 211.192 (2026)

Production record review

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 3 IN 5Y cited 1988–2025 9citing cases
At a glance

Courts have cited this section in 9 opinions since 1988, 3 of them in the last five years.

All drug product production and control records, including those for packaging and labeling, shall be reviewed and approved by the quality control unit to determine compliance with all established, approved written procedures before a batch is released or distributed. Any unexplained discrepancy (including a percentage of theoretical yield exceeding the maximum or minimum percentages established in master production and control records) or the failure of a batch or any of its components to meet any of its specifications shall be thoroughly investigated, whether or not the batch has already been distributed. The investigation shall extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy. A written record of the investigation shall be made and shall include the conclusions and followup.

The 9 cases that cite 21 C.F.R. § 211.192 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENCrocker v. Kv Pharm. Co., 782 F. Supp. 2d 760 (E.D. Mo. 2010).
cites § 211.192 2×cited by 12 cases
Where it cites § 211.192
“Failure to make written records of investigations into unexplained discrepancies and investigations of a batch or any of its components to meet specifications, as required by 21 C.F.R. § 211.192 ; d. Failure to review and approve drug product production and control records by…”
Later courts cite it for
“had knowledge of or participated in underlying fiduciary breaches.” · 2 citing courts
2
GREENMulligan v. Impax Labs., Inc., 36 F. Supp. 3d 942 (N.D. Cal. 2014).
cites § 211.192 1×cited by 14 cases
Where it cites § 211.192
“Both the Form 483 and subsequent EIR noted that these deficiencies were a violation of 21 C.F.R. § 211.192 which requires unexplained discrepancies to be thoroughly investigated.”
Later courts cite it for
“scienter may be 26 imputed 'based on the inference that key officers have knowledge of the 'core operations' of the 27 company.” · 2 citing courts
cites § 211.192 1×cited by 28 cases
Where it cites § 211.192
“at 29285; 21 C.F.R. § 211.192 (requiring “any unexplained discrepancy” in production and control records to be “thoroughly investigated,” and a “written report of the investigation” to be prepared).”
Later courts cite it for
“apply with equal force in the context of administrative judgment.” · 3 citing courts
4
REDPub. Pension Fund Grp. v. Kv Pharm. Co., 705 F. Supp. 2d 1088 (E.D. Mo. 2010).
cites § 211.192 2×cited by 4 cases
Reversed in part by Public Pension Fund Group v. KV PHARMACEUTICAL CO. (2012): the Court of Appeals for the Eighth Circuit's own opinion in this case ("Ill For the reasons stated, we affirm in part, reverse in part, and remand to…
Where it cites § 211.192
“Failure to make written records of investigations into unexplained discrepancies and the failure to make written records of investigations of a batch or any of its components to meet specifications, as required by 21 C.F.R. § 211.192 ; D. Failure to review and approve drug…”
5
GREENUnited States v. Merck & Co., 44 F. Supp. 3d 581 (E.D. Pa. 2014).
cites § 211.192 1×cited by 9 cases
Where it cites § 211.192
“§ 331 (c); 21 C.F.R. § 211.192 . (Dkt. No. 12 ¶ 115.”
6
GREENUnited States v. Barr Labs., Inc., 812 F. Supp. 458 (D.N.J. 1993).
cites § 211.192 1×cited by 13 cases
Where it cites § 211.192
“21 C.F.R. § 211.192 ; see (924:19 (Ger-raughty) (violation of CGMP to discard out-of-specification results and pass batch on retesting alone)).”
7
NO FLAGPfizer Inc. v. State of Texas & Tarik Ahmed, No. 15-25-00021-CV (Tex. App.—15th Dist. Feb. 28, 2025).
cites § 211.192 3×cited by 0 cases
Where it cites § 211.192
“Through these CGMP regulations, the FDA requires pharmaceutical manufacturers to institute standard processes for evaluating the quality of their products and to thoroughly investigate complaints about their products as well as unexplained discrepancies in product quality.”
8
NO FLAGPfizer Inc. v. State of Texas & Tarik Ahmed, No. 15-25-00021-CV (Tex. App.—15th Dist. Mar. 10, 2025).
cites § 211.192 3×cited by 0 cases
Where it cites § 211.192
“16 We cite 21 CFR 211.192 in paragraph 21, 17 which talks about production control records.”
9
NO FLAGDaugherty v. Padagis Israel Pharm. Ltd., No. 3:24-cv-02066 (N.D. Cal. Aug. 6, 2025).
cites § 211.192 1×cited by 0 casesunknown
Where it cites § 211.192
“9 21 C.F.R. § 211.192 (emphasis added). What constitutes a “thorough” investigation, such that a 10 manufacturer can be said to have complied with § 211.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198820062025

One bar per year. Tallest: 3 cases in 2025. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
N.D. Cal.2E.D. Mo.2Tex. App.2D.C. Cir.1D.N.J.1E.D. Pa.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com